Natalia V. Pozdniakova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natalia V. Pozdniakova has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Aleksei B Shevelev
Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia
11 shared publications - Yulia K. Biryukova
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis)
7 shared publications - E. S. Severin
Russian Research Center for Molecular Diagnostics and Therapy
5 shared publications - Elena Vladimirovna Trubnikova
Kursk State University, Kursk, Russia
4 shared publications - Evgenii Aleksandrovich Generalov
Department of Biophysics, Faculty of Physics, Lomonosov Moscow State University, 119991 Moscow, Russia
4 shared publications S. E. Severin
NBIC-center
4 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by American Chemical Society (ACS) in ACS Omega
Long-Term Biodistribution and Safety Profile of Laser-Generated Gold Nanoparticles Following High-Dose Administration in Mice
Gold nanoparticles (AuNPs) have emerged as versatile agents for a wide range of biomedical applications, including imaging, diagnostics, and therapy. While their use in modalities such as CT imaging and radiotherapy is particularly promising, these applications require high systemic doses (≥500 mg Au/kg), necessitating thorough evaluation of long-term biodistribution and safety profiles. Here, we present a comprehensive one-year assessment of Polyethylene glycol (PEG) -coated laser-synthesized AuNPs (mean core diameter ∼8 nm). After intravenous administration at a high dose, biodistribution was evaluated in healthy mice (n = 8; 874 ± 56 mg Au/kg) using a serial CT imaging, with terminal ICP-AES validation, blood biochemistry, and histology performed in 5 of these animals. AuNPs exhibited prolonged blood circulation (half-life 21 ± 3 h) and accumulated predominantly in reticuloendothelial organs: 42.2 ± 3.6%ID/cm3 in the liver and 40.2 ± 3.3%ID/cm3 in the spleen, with one-year retention of 77.5% and 83.1%, respectively. Despite substantial hepatic and splenic retention, no histopathological changes were detected in any major organs, including kidney and liver. Serum biochemical markers of liver, kidney, and pancreatic function revealed no statistically significant differences between the treated and control groups. Only a slight elevation in aspartate aminotransferase (AST) was observed in two treated animals (184.1 and 187.8 U/L vs 118.3 ± 18.4 U/L in the control group), while all other liver function markers (ALT, alkaline phosphatase, bilirubin) remained unaltered. Additionally, tumor uptake was evaluated in two separate cohorts of mice bearing subcutaneous tumor models, mammary adenocarcinoma Ca755 (n = 3, 809 ± 28 mg Au/kg) and melanoma B16F10 (n = 3, 814 ± 45 mg Au/kg). AuNPs accumulated in tumor tissue, reaching 9.4 ± 1.9%ID/cm3 for Ca755 and 5.3 ± 1.1%ID/cm3 for B16F10. Overall, these results provide insight into the safety profile and tumor uptake of laser-synthesized AuNPs, supporting their potential as a platform for novel radiosensitizers and contrast agents.
- 5 November 2026
- Published by American Chemical Society (ACS) in ACS Omega
Open AccessLong-Term Biodistribution and Safety Profile of Laser-Generated Gold Nanoparticles Following High-Dose Administration in Mice
Gold nanoparticles (AuNPs) have emerged as versatile agents for a wide range of biomedical applications, including imaging, diagnostics, and therapy. While their use in modalities such as CT imaging and radiotherapy is particularly promising, these applications require high systemic doses (≥500 mg Au/kg), necessitating thorough evaluation of long-term biodistribution and safety profiles. Here, we present a comprehensive one-year assessment of Polyethylene glycol (PEG) -coated laser-synthesized AuNPs (mean core diameter ∼8 nm). After intravenous administration at a high dose, biodistribution was evaluated in healthy mice (n = 8; 874 ± 56 mg Au/kg) using a serial CT imaging, with terminal ICP-AES validation, blood biochemistry, and histology performed in 5 of these animals. AuNPs exhibited prolonged blood circulation (half-life 21 ± 3 h) and accumulated predominantly in reticuloendothelial organs: 42.2 ± 3.6%ID/cm3 in the liver and 40.2 ± 3.3%ID/cm3 in the spleen, with one-year retention of 77.5% and 83.1%, respectively. Despite substantial hepatic and splenic retention, no histopathological changes were detected in any major organs, including kidney and liver. Serum biochemical markers of liver, kidney, and pancreatic function revealed no statistically significant differences between the treated and control groups. Only a slight elevation in aspartate aminotransferase (AST) was observed in two treated animals (184.1 and 187.8 U/L vs 118.3 ± 18.4 U/L in the control group), while all other liver function markers (ALT, alkaline phosphatase, bilirubin) remained unaltered. Additionally, tumor uptake was evaluated in two separate cohorts of mice bearing subcutaneous tumor models, mammary adenocarcinoma Ca755 (n = 3, 809 ± 28 mg Au/kg) and melanoma B16F10 (n = 3, 814 ± 45 mg Au/kg). AuNPs accumulated in tumor tissue, reaching 9.4 ± 1.9%ID/cm3 for Ca755 and 5.3 ± 1.1%ID/cm3 for B16F10. Overall, these results provide insight into the safety profile and tumor uptake of laser-synthesized AuNPs, supporting their potential as a platform for novel radiosensitizers and contrast agents.
- Open Access
Albumin-Coated Gold Nanoparticles Functionalised with a Gadolinium-Binding Recombinant Protein for Dual CT/MR Imaging
Gold nanoparticles (AuNPs) are versatile nanomaterial scaffolds for imaging and multifunctional platform development; however, biologically addressable multicomponent coatings often require multistep chemistry that can limit accessibility and reproducibility. Here, we report a one-pot, albumin-mediated synthesis of human serum albumin (HSA)-coated gold nanoparticles (Au–HSA) and their modular functionalisation with F3del-ABD-GFP (FAG), an engineered protein that combines a high-affinity albumin-binding domain with a de novo gadolinium-binding domain. Two preparations, Au–HSA1 and Au–HSA2, with UV–Vis-derived apparent core diameters of approximately 5 and 16 nm, respectively, were obtained by reduction of sodium tetrachloroaurate(III) in the presence of HSA and characterised by UV–Vis spectroscopy, dynamic light scattering, zeta-potential analysis, ICP–AES, SDS–PAGE densitometry, and atomic force microscopy. Recovered-gold yields were 74.8 ± 11.2% (Au–HSA1) and 84.6 ± 9.2% (Au–HSA2). Albumin remained particle-bound in SDS under non-reducing conditions, consistent with thiol-mediated attachment, with an estimated average of approximately 14 HSA molecules per Au–HSA2 particle, calculated using the UV–Vis-derived particle concentration. FAG bound the particle-associated albumin near-stoichiometrically, and pre-loaded FAG:Gd associated with Au–HSA2 under the tested assembly conditions, giving an estimated average batch composition AuNP:HSA:FAG:Gd of 1:14:14:56. In phantom samples, the assembled Au–HSA/FAG:Gd formulation generated qualitative CT and T1-weighted MR signal under the applied acquisition conditions. These imaging findings are qualitative; CT attenuation was not calibrated in Hounsfield units, and MR relaxivity was not determined. No biological, in vivo, safety, or therapeutic studies were performed. Accordingly, the system is presented as a physicochemical proof-of-concept for a modular dual CT/MR imaging platform. Its biological performance, quantitative imaging characteristics, and therapeutic utility require evaluation in future work.
Open AccessAlbumin-Coated Gold Nanoparticles Functionalised with a Gadolinium-Binding Recombinant Protein for Dual CT/MR Imaging
Gold nanoparticles (AuNPs) are versatile nanomaterial scaffolds for imaging and multifunctional platform development; however, biologically addressable multicomponent coatings often require multistep chemistry that can limit accessibility and reproducibility. Here, we report a one-pot, albumin-mediated synthesis of human serum albumin (HSA)-coated gold nanoparticles (Au–HSA) and their modular functionalisation with F3del-ABD-GFP (FAG), an engineered protein that combines a high-affinity albumin-binding domain with a de novo gadolinium-binding domain. Two preparations, Au–HSA1 and Au–HSA2, with UV–Vis-derived apparent core diameters of approximately 5 and 16 nm, respectively, were obtained by reduction of sodium tetrachloroaurate(III) in the presence of HSA and characterised by UV–Vis spectroscopy, dynamic light scattering, zeta-potential analysis, ICP–AES, SDS–PAGE densitometry, and atomic force microscopy. Recovered-gold yields were 74.8 ± 11.2% (Au–HSA1) and 84.6 ± 9.2% (Au–HSA2). Albumin remained particle-bound in SDS under non-reducing conditions, consistent with thiol-mediated attachment, with an estimated average of approximately 14 HSA molecules per Au–HSA2 particle, calculated using the UV–Vis-derived particle concentration. FAG bound the particle-associated albumin near-stoichiometrically, and pre-loaded FAG:Gd associated with Au–HSA2 under the tested assembly conditions, giving an estimated average batch composition AuNP:HSA:FAG:Gd of 1:14:14:56. In phantom samples, the assembled Au–HSA/FAG:Gd formulation generated qualitative CT and T1-weighted MR signal under the applied acquisition conditions. These imaging findings are qualitative; CT attenuation was not calibrated in Hounsfield units, and MR relaxivity was not determined. No biological, in vivo, safety, or therapeutic studies were performed. Accordingly, the system is presented as a physicochemical proof-of-concept for a modular dual CT/MR imaging platform. Its biological performance, quantitative imaging characteristics, and therapeutic utility require evaluation in future work.
- Open Access
- 31 March 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (4) , 431
RNA Therapeutics in Viral Infections and Cancer: Mechanisms, Challenges, and Prospects: A Review
Background: RNA therapeutics represent a rapidly advancing field with significant potential for treating viral infections and cancer. This review examines the current landscape of RNA-based strategies, including siRNA, miRNA mimics, and antisense oligonucleotides. For viral infections, the focus is on hepatitis B (HBV) and C (HCV), HIV, and SARS-CoV-2. Approaches include targeting viral transcripts directly (e.g., siRNAs against HBV surface antigen) or host factors critical for viral replication (e.g., anti-miR-122 miravirsen for HCV). The successful development of mRNA vaccines for COVID-19 is highlighted as a major breakthrough, demonstrating the feasibility of rapid RNA vaccine deployment. The manuscript reviews several RNA therapeutics in oncology that have reached clinical trials. These include TargomiR (a miR-16 mimic for mesothelioma), cobomarsen (an anti-miR-155 for lymphomas), and MRX34 (a miR-34a mimic for various solid tumours). The review also covers emerging candidates like an miR-221 inhibitor and various strategies for breast cancer, such as targeting Bcl-2, KRAS, and specific miRNAs. A critical challenge across both fields is developing efficient and safe delivery systems, including lipid nanoparticles, GalNAc conjugates, and bacterial minicells. Despite promising preclinical results, clinical translation has been hampered by issues like insufficient delivery efficiency to human tumours, toxicity, and the complex, interconnected regulatory networks of miRNAs, which can lead to unpredictable off-target effects. Conclusions: While RNA therapeutics hold immense promise, overcoming delivery barriers and enhancing understanding of RNA regulatory networks are essential for future success.
- 31 March 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (4) , 431
Open AccessRNA Therapeutics in Viral Infections and Cancer: Mechanisms, Challenges, and Prospects: A Review
Background: RNA therapeutics represent a rapidly advancing field with significant potential for treating viral infections and cancer. This review examines the current landscape of RNA-based strategies, including siRNA, miRNA mimics, and antisense oligonucleotides. For viral infections, the focus is on hepatitis B (HBV) and C (HCV), HIV, and SARS-CoV-2. Approaches include targeting viral transcripts directly (e.g., siRNAs against HBV surface antigen) or host factors critical for viral replication (e.g., anti-miR-122 miravirsen for HCV). The successful development of mRNA vaccines for COVID-19 is highlighted as a major breakthrough, demonstrating the feasibility of rapid RNA vaccine deployment. The manuscript reviews several RNA therapeutics in oncology that have reached clinical trials. These include TargomiR (a miR-16 mimic for mesothelioma), cobomarsen (an anti-miR-155 for lymphomas), and MRX34 (a miR-34a mimic for various solid tumours). The review also covers emerging candidates like an miR-221 inhibitor and various strategies for breast cancer, such as targeting Bcl-2, KRAS, and specific miRNAs. A critical challenge across both fields is developing efficient and safe delivery systems, including lipid nanoparticles, GalNAc conjugates, and bacterial minicells. Despite promising preclinical results, clinical translation has been hampered by issues like insufficient delivery efficiency to human tumours, toxicity, and the complex, interconnected regulatory networks of miRNAs, which can lead to unpredictable off-target effects. Conclusions: While RNA therapeutics hold immense promise, overcoming delivery barriers and enhancing understanding of RNA regulatory networks are essential for future success.
- Open Access
- 7 October 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (10) , 1305
RNA Therapeutics: Delivery Problems and Solutions—A Review
RNA-based therapeutics offer transformative potential for treating devastating diseases. However, current RNA delivery technologies face significant hurdles, including inefficient tissue targeting, insufficient selectivity, and severe side effects, leading to the termination of many clinical trials. This review critically assesses the landscape of RNA-derived medicines, examining world-renowned mRNA vaccines (Spikevax, BNT162b2/Comirnaty) and RNA-based therapeutics like Miravirsen (anti-miR-122). It details the composition and clinical trial results of numerous modified short RNA drugs (e.g., siRNAs, miRNA mimetics/inhibitors) targeting various conditions. Prospects for RNA-based medicines are analysed for diseases with substantial societal impact, such as cancer, autoimmune disorders, and infectious diseases, with a focus on evolving delivery methods, including lipid nanoparticles, viral vectors, and exosomes. RNA-mediated macrophage reprogramming emerges as a promising strategy, potentially enhancing both delivery and clinical efficacy. This review highlights that while approved RNA therapies primarily target rare diseases due to delivery limitations, novel approaches in RNA modification, targeted delivery systems, and enhanced understanding of molecular mechanisms are crucial for expanding their application to prevalent diseases and unlocking their full therapeutic potential.
- 7 October 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (10) , 1305
Open AccessRNA Therapeutics: Delivery Problems and Solutions—A Review
RNA-based therapeutics offer transformative potential for treating devastating diseases. However, current RNA delivery technologies face significant hurdles, including inefficient tissue targeting, insufficient selectivity, and severe side effects, leading to the termination of many clinical trials. This review critically assesses the landscape of RNA-derived medicines, examining world-renowned mRNA vaccines (Spikevax, BNT162b2/Comirnaty) and RNA-based therapeutics like Miravirsen (anti-miR-122). It details the composition and clinical trial results of numerous modified short RNA drugs (e.g., siRNAs, miRNA mimetics/inhibitors) targeting various conditions. Prospects for RNA-based medicines are analysed for diseases with substantial societal impact, such as cancer, autoimmune disorders, and infectious diseases, with a focus on evolving delivery methods, including lipid nanoparticles, viral vectors, and exosomes. RNA-mediated macrophage reprogramming emerges as a promising strategy, potentially enhancing both delivery and clinical efficacy. This review highlights that while approved RNA therapies primarily target rare diseases due to delivery limitations, novel approaches in RNA modification, targeted delivery systems, and enhanced understanding of molecular mechanisms are crucial for expanding their application to prevalent diseases and unlocking their full therapeutic potential.
- Open Access
- 5 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8651
siRNA Therapeutics for the Treatment of Hereditary Diseases and Other Conditions: A Review
RNA-based drugs hold significant potential, offering promising new treatments for a wide range of diseases, especially those with a genetic basis. By leveraging RNA interference (RNAi) and other RNA-mediated mechanisms, these therapies can precisely modulate gene expression and address the root causes of genetic defects. RNA-based drugs hold significant potential for treating a range of diseases. However, the transition of these therapies from laboratory research to clinical applications has encountered hurdles. This review explores the composition and outcomes of clinical trials for various modified short RNA drugs. We detail their mechanisms of action, delivery systems—with a focus on lipid nanoparticles and N-acetylgalactosamine (GalNAc) conjugates—and clinical efficacy in treating conditions such as transthyretin (TTR) amyloidosis. Our analysis reveals that while several RNAi-based drugs have achieved clinical approval, a critical unmet need remains: advanced delivery systems capable of precisely targeting diverse tissues, particularly outside the liver. We also underscore the importance of rigorous target validation utilising sophisticated bioinformatics tools and in vitro/in vivo assays to minimise off-target effects and ensure robust therapeutic efficacy. This review proposes a novel framework for optimising RNA drug development, emphasising the crucial interplay between delivery strategies, target specificity, and understanding disease-specific target biology.
- 5 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8651
Open AccesssiRNA Therapeutics for the Treatment of Hereditary Diseases and Other Conditions: A Review
RNA-based drugs hold significant potential, offering promising new treatments for a wide range of diseases, especially those with a genetic basis. By leveraging RNA interference (RNAi) and other RNA-mediated mechanisms, these therapies can precisely modulate gene expression and address the root causes of genetic defects. RNA-based drugs hold significant potential for treating a range of diseases. However, the transition of these therapies from laboratory research to clinical applications has encountered hurdles. This review explores the composition and outcomes of clinical trials for various modified short RNA drugs. We detail their mechanisms of action, delivery systems—with a focus on lipid nanoparticles and N-acetylgalactosamine (GalNAc) conjugates—and clinical efficacy in treating conditions such as transthyretin (TTR) amyloidosis. Our analysis reveals that while several RNAi-based drugs have achieved clinical approval, a critical unmet need remains: advanced delivery systems capable of precisely targeting diverse tissues, particularly outside the liver. We also underscore the importance of rigorous target validation utilising sophisticated bioinformatics tools and in vitro/in vivo assays to minimise off-target effects and ensure robust therapeutic efficacy. This review proposes a novel framework for optimising RNA drug development, emphasising the crucial interplay between delivery strategies, target specificity, and understanding disease-specific target biology.
- 31 August 2025
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 8_2025, 159-171
Exploration of protein PCP4 as a potential tumor marker in uterine leiomyoma
- 31 August 2025
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 8_2025, 159-171
Exploration of protein PCP4 as a potential tumor marker in uterine leiomyoma
- 1 October 2024
- Published by Pleiades Publishing Ltd in Biophysics
- Vol. 69 (5) , 882-891
Cytotoxicity of Selenium Nanoparticles Synthesized with the Artificial W8-C3 Metal-Binding Tumor-Targeting Protein
The pW8-3C construct encoding the artificial tumor-targeting protein W8-3C with the addition of three residues of free Cys at the C terminus has been created and described for the first time. Using purified W8-3C protein, dispersions of nanoparticles 75.24 nm in diameter at a polydispersity index (Pdi) of 0.064 and Se content of 1.566 μg/mL were obtained and characterized for the first time. The dispersions remained stable during storage for 6 months at +4°C. For comparison, the maximum Se content in the nanoparticle dispersion obtained in the presence of W8-3C protein and Pluronic F-127 was 399 μg/mL. The cytotoxic activity of the obtained nanoparticles was studied on HeLa (cervical carcinoma), U87MG (glioma), MCF7 (breast carcinoma), and HCT116 (colon carcinoma) human tumor cell lines and compared with that on the diploid human fibroblast line WI-38 in vitro. It was shown that the IC50 of Se nanoparticles obtained using the W8-3C protein for tumor lines ranged from 5.25 to 8.37 μg/mL, while the IC50 for normal fibroblasts was 14.3 μg/mL (difference in values by a factor of 1.7–2.7 times).
- 1 October 2024
- Published by Pleiades Publishing Ltd in Biophysics
- Vol. 69 (5) , 882-891
Cytotoxicity of Selenium Nanoparticles Synthesized with the Artificial W8-C3 Metal-Binding Tumor-Targeting Protein
The pW8-3C construct encoding the artificial tumor-targeting protein W8-3C with the addition of three residues of free Cys at the C terminus has been created and described for the first time. Using purified W8-3C protein, dispersions of nanoparticles 75.24 nm in diameter at a polydispersity index (Pdi) of 0.064 and Se content of 1.566 μg/mL were obtained and characterized for the first time. The dispersions remained stable during storage for 6 months at +4°C. For comparison, the maximum Se content in the nanoparticle dispersion obtained in the presence of W8-3C protein and Pluronic F-127 was 399 μg/mL. The cytotoxic activity of the obtained nanoparticles was studied on HeLa (cervical carcinoma), U87MG (glioma), MCF7 (breast carcinoma), and HCT116 (colon carcinoma) human tumor cell lines and compared with that on the diploid human fibroblast line WI-38 in vitro. It was shown that the IC50 of Se nanoparticles obtained using the W8-3C protein for tumor lines ranged from 5.25 to 8.37 μg/mL, while the IC50 for normal fibroblasts was 14.3 μg/mL (difference in values by a factor of 1.7–2.7 times).
- Open Access
- 23 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10197
Transplanted Murine Tumours SPECT Imaging with 99mTc Delivered with an Artificial Recombinant Protein
99mTc is a well-known radionuclide that is widely used and readily available for SPECT/CT (Single-Photon Emission Computed Tomography) diagnosis. However, commercial isotope carriers are not specific enough to tumours, rapidly clear from the bloodstream, and are not safe. To overcome these limitations, we suggest immunologically compatible recombinant proteins containing a combination of metal binding sites as 99mTc chelators and several different tumour-specific ligands for early detection of tumours. E1b protein containing metal-binding centres and tumour-specific ligands targeting integrin αvβ3 and nucleolin, as well as a short Cys-rich sequence, was artificially constructed. It was produced in E. coli, purified by metal-chelate chromatography, and used to obtain a complex with 99mTc. This was administered intravenously to healthy Balb/C mice at an activity dose of about 80 MBq per mouse, and the biodistribution was studied by SPECT/CT for 24 h. Free sodium 99mTc-pertechnetate at the same dose was used as a reference. The selectivity of 99mTc-E1b and the kinetics of isotope retention in tumours were then investigated in experiments in C57Bl/6 and Balb/C mice with subcutaneously transplanted lung carcinoma (LLC) or mammary adenocarcinoma (Ca755, EMT6, or 4T1). The radionuclide distribution ratio in tumour and adjacent normal tissue (T/N) steadily increased over 24 h, reaching 15.7 ± 4.2 for EMT6, 16.5 ± 3.8 for Ca755, 6.7 ± 4.2 for LLC, and 7.5 ± 3.1 for 4T1.
- 23 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10197
Open AccessTransplanted Murine Tumours SPECT Imaging with 99mTc Delivered with an Artificial Recombinant Protein
99mTc is a well-known radionuclide that is widely used and readily available for SPECT/CT (Single-Photon Emission Computed Tomography) diagnosis. However, commercial isotope carriers are not specific enough to tumours, rapidly clear from the bloodstream, and are not safe. To overcome these limitations, we suggest immunologically compatible recombinant proteins containing a combination of metal binding sites as 99mTc chelators and several different tumour-specific ligands for early detection of tumours. E1b protein containing metal-binding centres and tumour-specific ligands targeting integrin αvβ3 and nucleolin, as well as a short Cys-rich sequence, was artificially constructed. It was produced in E. coli, purified by metal-chelate chromatography, and used to obtain a complex with 99mTc. This was administered intravenously to healthy Balb/C mice at an activity dose of about 80 MBq per mouse, and the biodistribution was studied by SPECT/CT for 24 h. Free sodium 99mTc-pertechnetate at the same dose was used as a reference. The selectivity of 99mTc-E1b and the kinetics of isotope retention in tumours were then investigated in experiments in C57Bl/6 and Balb/C mice with subcutaneously transplanted lung carcinoma (LLC) or mammary adenocarcinoma (Ca755, EMT6, or 4T1). The radionuclide distribution ratio in tumour and adjacent normal tissue (T/N) steadily increased over 24 h, reaching 15.7 ± 4.2 for EMT6, 16.5 ± 3.8 for Ca755, 6.7 ± 4.2 for LLC, and 7.5 ± 3.1 for 4T1.
- Open Access
- 9 August 2024
- Published by MDPI AG in Preprints.org
Transplanted Murine Tumours SPECT Imaging with 99mTc Delivered with an Artificial Recombinant Protein
99mTc is a well-known radionuclide widely used and readily available for medical imaging. Despite this, the 99mTc isotope is rarely utilized for tumour imaging due to the lack of agents that can selectively deliver it to tumours. However, the use of immunologically compatible recombinant proteins, which combine metal-binding sites and tumour-specific ligands, shows promise for utilizing 99mTc in the early detection of tumours. To illustrate this, a protein called E1b, containing a metal binding center with ELP repeats, tumour-specific ligands recognizing integrin αvβ3 and nucleolin, as well as a short Cys-rich sequence, was artificially designed. This protein was produced in E. coli and purified to homogeneity using metal-chelate chromatography. In experiments, C57Bl/6 and Balb/C mice with subcutaneously grafted lung carcinoma (LLC) or mammary gland adenocarcinoma (Ca755, EMT6, or 4T1) were used to test 99mTc-E1b selectivity and the kinetics of isotope retention. The mice were intravenously injected with approximately 80 MBq of 99mTc in complex with E1b, which had been freshly purified using gel-chromatography. The biodistribution of the labeled protein was then studied using the SPECT/CT imaging method within 24 h. The ratio of radionuclide distribution in the tumour versus the adjacent normal tissue (T/N) steadily increased over the 24-h period, reaching 15.7±4.2 for EMT6, 16.5±3.8 for Ca755, 6.7±4.2 for LLC, and 7.5±3.1 for 4T1.
- 9 August 2024
- Published by MDPI AG in Preprints.org
Open AccessTransplanted Murine Tumours SPECT Imaging with 99mTc Delivered with an Artificial Recombinant Protein
99mTc is a well-known radionuclide widely used and readily available for medical imaging. Despite this, the 99mTc isotope is rarely utilized for tumour imaging due to the lack of agents that can selectively deliver it to tumours. However, the use of immunologically compatible recombinant proteins, which combine metal-binding sites and tumour-specific ligands, shows promise for utilizing 99mTc in the early detection of tumours. To illustrate this, a protein called E1b, containing a metal binding center with ELP repeats, tumour-specific ligands recognizing integrin αvβ3 and nucleolin, as well as a short Cys-rich sequence, was artificially designed. This protein was produced in E. coli and purified to homogeneity using metal-chelate chromatography. In experiments, C57Bl/6 and Balb/C mice with subcutaneously grafted lung carcinoma (LLC) or mammary gland adenocarcinoma (Ca755, EMT6, or 4T1) were used to test 99mTc-E1b selectivity and the kinetics of isotope retention. The mice were intravenously injected with approximately 80 MBq of 99mTc in complex with E1b, which had been freshly purified using gel-chromatography. The biodistribution of the labeled protein was then studied using the SPECT/CT imaging method within 24 h. The ratio of radionuclide distribution in the tumour versus the adjacent normal tissue (T/N) steadily increased over the 24-h period, reaching 15.7±4.2 for EMT6, 16.5±3.8 for Ca755, 6.7±4.2 for LLC, and 7.5±3.1 for 4T1.
- Open Access
- 18 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 3297
Using ELP Repeats as a Scaffold for De Novo Construction of Gadolinium-Binding Domains within Multifunctional Recombinant Proteins for Targeted Delivery of Gadolinium to Tumour Cells
Three artificial proteins that bind the gadolinium ion (Gd3+) with tumour-specific ligands were de novo engineered and tested as candidate drugs for binary radiotherapy (BRT) and contrast agents for magnetic resonance imaging (MRI). Gd3+-binding modules were derived from calmodulin. They were joined with elastin-like polypeptide (ELP) repeats from human elastin to form the four-centre Gd3+-binding domain (4MBS-domain) that further was combined with F3 peptide (a ligand of nucleolin, a tumour marker) to form the F3-W4 block. The F3-W4 block was taken alone (E2-13W4 protein), as two repeats (E1-W8) and as three repeats (E1-W12). Each protein was supplemented with three copies of the RGD motif (a ligand of integrin αvβ3) and green fluorescent protein (GFP). In contrast to Magnevist (a Gd-containing contrast agent), the proteins exhibited three to four times higher accumulation in U87MG glioma and A375 melanoma cell lines than in normal fibroblasts. The proteins remained for >24 h in tumours induced by Ca755 adenocarcinoma in C57BL/6 mice. They exhibited stability towards blood proteases and only accumulated in the liver and kidney. The technological advantages of using the engineered proteins as a basis for developing efficient and non-toxic agents for early diagnosis of tumours by MRI as well as part of BRT were demonstrated.
- 18 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 3297
Open AccessUsing ELP Repeats as a Scaffold for De Novo Construction of Gadolinium-Binding Domains within Multifunctional Recombinant Proteins for Targeted Delivery of Gadolinium to Tumour Cells
Three artificial proteins that bind the gadolinium ion (Gd3+) with tumour-specific ligands were de novo engineered and tested as candidate drugs for binary radiotherapy (BRT) and contrast agents for magnetic resonance imaging (MRI). Gd3+-binding modules were derived from calmodulin. They were joined with elastin-like polypeptide (ELP) repeats from human elastin to form the four-centre Gd3+-binding domain (4MBS-domain) that further was combined with F3 peptide (a ligand of nucleolin, a tumour marker) to form the F3-W4 block. The F3-W4 block was taken alone (E2-13W4 protein), as two repeats (E1-W8) and as three repeats (E1-W12). Each protein was supplemented with three copies of the RGD motif (a ligand of integrin αvβ3) and green fluorescent protein (GFP). In contrast to Magnevist (a Gd-containing contrast agent), the proteins exhibited three to four times higher accumulation in U87MG glioma and A375 melanoma cell lines than in normal fibroblasts. The proteins remained for >24 h in tumours induced by Ca755 adenocarcinoma in C57BL/6 mice. They exhibited stability towards blood proteases and only accumulated in the liver and kidney. The technological advantages of using the engineered proteins as a basis for developing efficient and non-toxic agents for early diagnosis of tumours by MRI as well as part of BRT were demonstrated.